October 11, 2017 04:31 PM EDT
R&D
Pharma

Bat­tered by mixed PhI­II da­ta, Treve­na ax­es R&D staff and hun­kers down around lead pain drug

John Carroll

Editor & Founder

Eight months af­ter Treve­na {TRVN} was ham­mered over some mixed Phase III re­sults for its new pain ther­a­py, the biotech is slash­ing its re­search group …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times